Remodeling Translation Primes CD8+ T-cell Antitumor Immunity

Cancer Immunol Res. 2020 May;8(5):587-595. doi: 10.1158/2326-6066.CIR-19-0516. Epub 2020 Feb 19.

Abstract

The requisites for protein translation in T cells are poorly understood and how translation shapes the antitumor efficacy of T cells is unknown. Here we demonstrated that IL15-conditioned T cells were primed by the metabolic energy sensor AMP-activated protein kinase to undergo diminished translation relative to effector T cells. However, we showed that IL15-conditioned T cells exhibited a remarkable capacity to enhance their protein translation in tumors, which effector T cells were unable to duplicate. Studying the modulation of translation for applications in cancer immunotherapy revealed that direct ex vivo pharmacologic inhibition of translation elongation primed robust T-cell antitumor immunity. Our work elucidates that altering protein translation in CD8+ T cells can shape their antitumor capability.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes / immunology*
  • Cell Line, Tumor
  • Coculture Techniques
  • Disease Models, Animal
  • Female
  • Immunotherapy / methods*
  • Interleukin-15 / metabolism
  • Lymphocyte Activation / immunology*
  • Mice
  • Mice, Inbred C57BL
  • Neoplasms / immunology*
  • Neoplasms / metabolism
  • Neoplasms / therapy
  • Peptide Elongation Factor 2 / metabolism*
  • Protein Biosynthesis*

Substances

  • Interleukin-15
  • Peptide Elongation Factor 2